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OBJECTIVE — The International Diabetes Mellitus Practice Study is a 5-year survey docu­
menting changes in diabetes treatment practice in developing regions.
RESEARCH DESIGN AND METHODS — Logistic regression analysis was used to 
identify factors for achieving A1C <7% in 11,799 patients (1,898 type 1 diabetic and 9,901 type 
2 diabetic) recruited by 937 physicians from 17 countries in Eastern Europe (n = 3,519), Asia 
(n = 5,888), Latin America (n = 2,116), and Africa (n = 276).
RESULTS— Twenty -two percent of type 1 diabetic and 36% of type 2 diabetic patients never had 
A1C measurements. In those with values for A1C, blood pressure, and LDL cholesterol, 7.5% of type 
1 diabetic (n = 696) and 3.6% of type 2 diabetic (n = 3,896) patients attained all three recommended 
targets (blood pressure <130/80 mmHg, LDL cholesterol <100 mg/dl, and A1C <7%). Self­
monitoring of blood glucose was the only predictor for achieving the A1C goal in type 1 diabetes 
(odds ratios: Asia 2.24, Latin America 3.55, and Eastern Europe 2.42). In type 2 diabetes, short 
disease duration (Asia 0.97, Latin America 0.97, and Eastern Europe 0.82) and treatment with few 
oral glucose-lowering drags (Asia 0.64, Latin America 0.76, and Eastern Europe 0.62) were predic­
tors. Other region-specific factors included lack of microvascular complications and old age in Latin 
America and Asia; health insurance coverage and specialist care in Latin America; lack of obesity and 
self-adjustment of insulin dosages in Asia; and training by a diabetes educator, self-monitoring of blood 
glucose in patients who self-adjusted insulin, and lack of macrovascular complications in Eastern Europe.
CONCLUSIONS — In developing countries, factors pertinent to patients, doctors, and 
health care systems all impact on glycemic control.
A
lthough optimizing diabetes care 
reduces death and complication 
rates (1-3), multiple barriers 
hinder turning evidence into practice 
(4,5). Most diabetic patients reside in de­
veloping countries (6) where standardized
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data on quality of care is relatively scarce. 
The International Diabetes Management 
Practices Study (IDMPS) is an ongoing ob­
servational survey to collect, analyze, and 
disseminate data in a standardized manner. 
By documenting changes in practices over 
••••••••••••••••••••••••• 
time in a broad range of health care settings, 
we aim to raise awareness and identify bar­
riers to quality diabetes care. Other objec­
tives include evaluation of clinical progress, 
levels of compliance, attainment of treat­
ment targets, and rates of hospitalization 
and work absenteeism. This analysis of the 
frrst-year survey examines factors predictive 
of glycemic control.
RESEARCH DESIGN AND 
METHODS— There are Eve waves in 
this 5-year study, each consisting of a 
2-week cross-sectional and a 9-month 
longitudinal survey. A 3-month interval 
separates the end of the longitudinal sur­
vey and the start of the next wave. Study 
design and reporting format are in accor­
dance with the recommended STROBE 
(Strengthening the Reporting of Observa­
tional Studies in Epidemiology) guide­
lines (7).
During the first wave, 18 countries 
recruited participants between 5 May and 
28 November 2005. These were Korea, 
China, Indonesia, India, Hong Kong, Tai­
wan, Malaysia, and Thailand from Asia 
(n = 5,888); Romania, Bulgaria, Turkey, 
Tunisia, and Bosnia from Eastern Europe 
(n = 3,519); Argentina, Ecuador, Vene­
zuela, and Colombia from Latin America 
(n = 2,116); and Tunisia from Africa (n = 
276). Physicians enrolled the first five 
type 1 diabetic and first 10 type 2 diabetic 
patients aged >18 years who attended 
their clinics over a 2-week period. Exclu­
sion criteria included active participation 
in a clinical study or recent short-term 
insulin treatment. Diabetes was defined 
by the 2002 World Health Organization 
criteria (8).
Data collection and outcome 
measures
Data were collected on case report forms 
for demographic and socioeconomic pro­
file, medical history, medications, glyce­
mic control, blood pressure and lipid 
status, self-care, access to patient educa­
tion, mode of follow-up, work absentee­
ism, and hospitalization. Outcome 
measures included attainment of treat­
ment goals defined as A1G <7%, blood 
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pressure <130/80 mmHg, and LDL cho­
lesterol <100 mg/dl (8).
Selection of physicians and sample 
size estimation
A main objective of the IDMPS is to doc­
ument the pattern of insulin usage. Thus, 
endocrinologists, diabetologists, and gen­
eral practitioners with experience in initi­
ation and titration of insulin therapy were 
invited to participate. The number of par­
ticipating physicians in each country was 
calculated according to estimated per­
centages of insulin-treated type 2 diabetic 
patients in the country. A total of 937 
physicians participated, with the highest 
enrollment in India (1,825 patients, 183 
physicians) and the lowest enrollment in 
Tunisia (361 patients, 37 physicians).
Study implementation
A steering committee advised the project 
team on study design and registry struc­
ture, monitored study progress, reviewed 
and validated all study-related docu­
ments, and proposed and approved deci­
sions on protocol amendments, analyses, 
and publications. The study was coordi­
nated by sanoh-aventis Intercontinental. In 
each country, the study was championed by 
a leading diabetologist who compiled and 
endorsed the list of investigators. The latter 
were assisted by local sanoh-aventis staff in 
collecting relevant information including 
clinical and laboratory parameters. Ethics 
approval was obtained from institutional 
boards of each country. All participants pro­
vided written informed consent.
Statistical analysis
All data were transferred from study cen­
ters to Mapi-Naxis, France, for quality 
control and analysis using SAS (version 
8.02; SAS Institute, Cary, NC). Descrip­
tive analysis, ANOVA, y2 test, and Fish­
er’s exact test were used as appropriate. 
Univariate and logistic regression analy­
ses were performed to identify predictive 
factors for A1C <7%. Age, duration of 
disease, and number of oral glucose- 
lowering drugs (OGEDs) were considered 
continuous variables. Due to regional het­
erogeneity, a logistic regression model per 
region was performed entering factors 
significant at the 10% level from the uni­
variate analysis. Odds ratios (ORs) with 
95% Cis were estimated for each signifi­
cant predictor. A backward selection pro­
cedure identified predictive factors that 
were significant at the 5% level. Relevant 
interactions (age X time since diagnosis, 
age X microvascular complications, age X 
macrovascular complications, time since di­
agnosis X microvascular complications, 
time since diagnosis X macrovascular com­
plications, BMI X microvascular compli­
cations, BMI X macrovascular 
complications, and self-monitoring of 
blood glucose [SMBG] X self-adjustment 
of insulin) were tested, and those signifi­
cant at the 10% level were added to the 
final model. A P value <0.05 (two-tailed) 
was considered significant. Because of the 
low number of patients recruited in Tuni­
sia, the data from this country were not 
included in the analysis.
RESULTS
Type 1 diabetes
Of the 1,898 type 1 diabetic patients re­
cruited by 937 physicians (Eastern Eu­
rope n = 914, Asia n = 512, Latin 
America n = 404, and Africa n = 68), 
20% reported diabetes-related hospital­
ization or work absenteeism in the last 6 
months, 22% never had A1C measured, 
and 10-30% were not screened for com­
plications in the last 24 months. Eastern 
Europe had the lowest proportion of 
screened patients. Clinical profiles were 
similar in all three regions (50% female, 
mean age 36 years, mean disease duration 
11.5 years), with the lowest BMI in Asia 
(Table 1).
Attainment of targets, treatment, 
and self care
Among patients with available A1C, 25% 
had a value <7 and 45% had attained 
blood pressure and LDL cholesterol goals. 
In patients with all three measurements 
(n = 696), 7.5% reached all three goals. 
Over 70% of patients performed SMBG, 
with the lowest percentage in Asia (Table 
1). Approximately 80% had health cover­
age and access to diabetes educators, 
whereas 16% belonged to a diabetes asso­
ciation. When stratified by SMBG and ac­
cess to diabetes educators, 29% of 
patients with both factors reached the 
A1C goal, compared with 21% with 
SMBG only, 14% with education only, 
and 8% with neither (P < 0.001).
The most popular insulin regimens 
were basal plus bolus in Latin America 
and Eastern Europe and a premix regimen 
in Asia. The mean insulin dose ranged 
from 0.5 to 0.8 IU/kg, with the highest 
dose used in the basal plus bolus regimen. 
Irrespective of treatment regimens or in­
sulin dose, 20-30% reached the A1C goal 
(data not shown).
Physicians’ perceptions and risk 
factor control
Physicians were to tickyes/no checkboxes 
for three questions: “Is the patient at tar­
get for glycemic control?,” “Is the patient 
suffering from hypertension?,” and “Is the 
patient suffering from dyslipidemia?” For 
glycemic control, they answered “yes” for 
717 (38%) patients, although 25% did 
not have an A1C value. For 483 patients 
without A1C, 38% were considered to be 
at target. For patients with A1C >7%, 
21% were considered to be at target, and 
for those with fasting blood glucose > 100 
mg/dl, 33% were considered to be at tar­
get. Similarly, 46% of patients untreated 
for hypertension had a blood pressure 
>130/80 mmHg, and 40% untreated for 
dyslipidemia had a LDL cholesterol level 
>100 mg/dl.
Predictors for glycemic control
There were few differences between pa­
tients with A1C <7% and >7% (Table 2). 
Only SMBG was associated with two- to 
threefold increased odds of reaching the 
A1C goal in all three regions. Short dis­
ease duration and training by diabetes ed­
ucators were predictors of glycemic 
control in Latin America (Fig. 1).
Type 2 diabetes
Of 9,901 type 2 diabetic patients re­
cruited by 937 physicians (Eastern Eu­
rope n = 2,605, Asia n = 5,376, Latin 
America n = 1,712, and Africa n = 208), 
10% reported diabetes-associated hospi­
talization or absenteeism from work in 
the last 6 months, 33% did not have 
health coverage, 36% never had A1C 
measured, and 11-36% were not 
screened for complications in the last 2 
years. There was marked regional hetero­
geneity for performance indexes, but for 
all three regions 20-40% of patients were 
at target for A1C, blood pressure, or lip­
ids. In patients with all three risk factors 
measured (n = 3,896), 3.6% attained all 
three targets. Clinical profiles were simi­
lar in the three regions (mean age 58 years 
and mean disease duration 8 years), with 
the lowest BMI and waist circumferences 
in Asia (Table 1).
Attainment of targets, treatment, 
and self-care
Insulin doses and regimens were similar 
in all three regions (data not shown). 
Overall, 3% of patients were treated with 
diet and exercise alone, 66% with OGLDs 
alone, and 31% with insulin, with or 
without OGLDs (details by country avail-
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able in the online appendix at http://dx. 
doi.org/10.2337/dc08-0435). Patients 
treated with insulin only had mean ± SD 
insulin doses ranging from 0.70 ± 0.35 
IU/kg in those using basal plus prandial 
insulin to 0.45 ± 0.21 IU/kg in those us­
ing basal insulin alone. Patients treated 
with OGLDs plus insulin had mean doses 
of 0.68 ± 0.29 IU/kg (basal plus prandial) 
and 0.35 ± 0.20 IU/kg (basal alone). Ir­
respective of region or insulin regimen, 
18-35% had A1G <7%. Overall, 42% 
never received diabetes education, 32% 
performed SMBG, and 8% belonged to a 
diabetes association.
Physician perception versus reality
Of patients considered by physicians to 
be at goal, 34% did not have an A1C value 
available. Of patients with A1C >7%, 
27% were considered to be at target, and 
of those whose fasting blood glucose was 
>100 mg/dl, 41% were considered to be 
at target. Among insulin-treated patients, 
22% with A1C >7% were considered to 
be at target. Among patients untreated for 
hypertension or dyslipidemia, 63% had a 
blood pressure >130/80 mmHg and 35% 
had LDL cholesterol >100 mg/dl.
Predictors for glycemic control
In all three regions, short disease duration 
was a predictor for A1C <7%. Region­
specific predictors were lack of microvas- 
cular complications and old age in Latin 
America and Asia; training by a diabetes 
educator, SMBG in patients who self­
adjusted insulin dosages, and lack of ma- 
crovascular complications in Eastern 
Europe; BMI <30 kg/m2 and self­
adjustment of insulin dosages in Asia; and 
management by specialists and having 
health insurance coverage in Latin Amer­
ica (Table 2, Fig. 2). In patients treated 
with OGLDs only, use of fewer OGLDs 
was a predictor for reaching target in all 
three regions (Fig. 3).
CONCLUSIONS— Th is multina­
tional survey confirms the chasm between 
guidelines and practice in Asia, Eastern 
Europe, and Latin America. Based on case 
records, 10-40% of patients were not 
screened for risk factors or complications 
in the last 24 months. Only 20-30% of 
patients were at the A1C goal, whereas 
7.5% of type 1 and 3.6% of type 2 diabetic 
patients attained three treatment goals. 
Furthermore, 20% of type 1 and 10% of 
type 2 diabetic patients reported hospital­
ization or work absenteeism in the past 6 
months. Such suboptimal performance 
indexes call for closer surveillance to im­
prove control.
Greater education needed
Whether managed by specialists or gen­
eral practitioners, patients had similar 
patterns of care and levels of control. In 
both types of diabetes, there was signifi­
cant mismatch between patient risk factor 
control and physician perception. Many 
physicians noted adequate glycemic con­
trol despite nonavailability of A1C mea­
surements, whereas others overestimated 
the proportions of patients at goal. This 
agrees with other reports of delayed esca­
lation in therapy (clinical inertia) and 
clinical assessments not translated into 
actions to improve control (9). Our End­
ings are also consistent with those re­
ported in Europe and the U.S., although 
reports from these regions show a slow 
trend of improvement in practice 
(10-12).
Predictors of glycemic control
In both diabetes types, although body 
weight-adjusted insulin doses were 
within recommended guidelines, neither 
doses nor regimens predicted glycemic 
control. SMBG was the only predictor for 
glycemic control in all three regions for 
type 1 diabetes. In Latin America, short 
disease duration and training by diabetes 
educators were also predictors: patients 
who had diabetes education and per­
formed SMBG were fourfold more likely 
to be at target than those with neither (29 
vs. 7%).
In type 2 diabetes, despite regional 
heterogeneity, short disease duration and 
use of few OGLDs were predictive factors 
in all three regions. In Asia and South 
America, absence of microvascular com­
plications was an additional predictor. 
These findings suggest that early diagno­
sis and prompt initiation of insulin ther­
apy in patients treated with multiple 
OGLDs may increase the likelihood of at­
taining glycemic targets, although defini­
tive studies are required. In Asia and 
South America, old age was a predictor, 
which agrees with data from the U.S. Di­
abetes Prevention Program, showing life­
style modification was more effective in 
elderly than young people (13), who may 
be less compliant because of competing 
priorities (14). In Asia, lack of obesity and 
self-adjustment of insulin dosages were 
predictors, emphasizing the double hit 
of obesity and p-cell insufficiency in 
Asian populations (15). Other region­
specific factors relevant to self-care
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Factor
SM8G 
ye* v» no
Duration of di*ea*o 
longer v» »hortar'*
Patient trained by 
diabetes educator 
yes vs no
Figure 1—Predietivefaetorsfor attaining A1C <7% in patients with type 1 diabetes, divided by regions.
ASIA LATIN AMERICA
OR (95% Cl)* OR (95% Cl)*
2.24 (1.194; 4.187) ----- 8------ 3.55 (1.209; 10 427) ------s------
NS 0.90 (0.929; 0.997) 1
NS 2.92 (1250; 6.355) -
0.1 10 0.1
I
10
Odds ratio (95% Cl)
(e.g., SMBG and self-adjustment of in­
sulin) and health care systems (e.g., 
health insurance coverage and access to 
specialists and diabetes educators) 
highlight the multiple challenges in op­
timizing diabetes care.
Strengths and weaknesses of our 
study
Whereas standardized methods used in 
the IDMPS allowed regional comparisons 
of diabetes practices, there are potential 
limitations including nonstandardized 
laboratory assays and assessments of 
complications. Selection of physicians ex­
perienced with insulin may introduce 
bias by overrepresenting patients with ad­
vanced diseases or complex regimens. 
However, the majority of patients were 
treated with OGLDs, and our analyses 
show that factors pertaining to the health 
care system, including access to educa­
tors, laboratory tests, and medications, 
are important barriers to achieving glyce­
mic control. Inferring from these End­
ings, we speculate that physicians with 
less system support and experience may 
face even greater challenges in managing 
these patients with multiple needs. De­
spite its cross-sectional nature, our data 
strongly suggest that prompt diagnosis, 
early intervention, and self-management 
are important determinants for glycemic 
control.
In conclusion, apart from contribut­
ing to the global landscape of diabetes 
practice, our data enable us to track per­
formance indexes over time and gener­
ate a hypothesis to explain suboptimal 
diabetes care. Our findings have quan­
tified factors pertinent to patients, care 
providers, and the health care system, 
all of which impact on the quality of 
diabetes care. There is an urgent need 
for the public, policy makers, and care
LATIN AMERICAASIAEASTERN EUROPE
Factor OR (95% Cl)* OR (95% Cl)* OR (95% Cl)*
Duration of disease: 
longer vs shorter13
0 92 (0.733; 0.913) ■ 0.97 (0.955; 0.980) 1 1 0.97 (0.951:0.987)
Age:
older vs younger0
NS - 1.02 (1.010; 1.024) 1 1.03 (1.014; 1.040)
Micro vascular 
complications; 
yes vs no
NS • 0.82 (0.693; 0.979) 0.47 (0.347; 0.641)
Macrovascuiar 
complications; 
yes vs no
0.51 (0.387; 0.676) NS NS -
Patient trained 
by diabetes educator: 
yes vs no
1.63 (1252:2.124) • NS NS -
SMBG: yes vs no
and
Self adjusts Insulin: yes
« NS NS
Patient self adjusts 
insulin: yes vs no
NS - 1.95 (1.424:2.679) * NS -
BMI
[30. 35] vs [18.5; 25]
NS - 0.64 (0.492; 0.829) NS -
BMI
>35 vs [19.5; 25]
NS - 0.53 (0.325; 0.860) NS -
Health Coverage; 
yes vs no
NS - NS - 2.38 (1.681; 3.369)
Physician speciality: 
Endocrinologists/ 
Diab-etologists 
vs others
NS - NS - 2.00 (1.533:2.620)
1
0.1 10 0.1
1
10
1
0.1
Odds ratio (95% Cl)
1
Figure 2—Predietivefaetorsfor attaining A1C <7% in patients with type 2 diabetes, divided by regions.
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Odds ratio (95% Cl)
EASTERN EUROPE ASIA LATIN AMERICA
Factor OR (95% Cl)’ OR (95% Ct)« OR (95% Cl)*
Number of 
OGLD treatments: 
more vs less’
0.62 (0.493; 0.768) -» 0.64 (0.566:0.733) ■ 0.76 (0.756: 0.999)
Age 
older vs younger
102 (1.003; 1.033) 1 1 1.01 (1.001. 1.022) 1 1.02 (1.002; 1.035) I 1
Duration of disease 
longer vs shorter* 1 2
NS - 0.86 (0.786:0.938) ■ 0.97 (0 944; 0.995) 1
Microvascular 
complications: 
yes vs no
NS - NS 0.43 (0.293; 0.632)
Macrovascular 
complications: 
yes vs no
0.49 (0.344; 0.696) ■ NS NS -
Patient trained by 
diabetes oducator 
yes vs no
1.72 (1.271; 2.320) NS NS -
SM8G 
yes vs no
NS - 1.34 (1.116; 1.616) « NS -
BMI
(30; 35) vs (18.5; 251
MS - 0.71 (0.529:0.964) ■ NS -
Health coverage: 
yes vs no
NS - NS 3.00 (1.935; 4 663) •
Physician speciality: 
Endocrinologists/ 
Diabetologists 
vs others
NS - NS 2.31 (1.640; 3.246) ■
0.1 10
1
01 10
1
0.1
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